Norgine Ventures completes €2 million financing with pritidenta
LONDON, UK. 7 November 2017, 08:35 AM GMT. Norgine Ventures announced today that it has provided financing of up to €2 million to pritidenta® GmbH, a company based in Leinfelden-Echterdingen, Germany, which develops and sells innovative materials for use in prosthetic dental products. This investment recognises pritidenta®’s best-in-class aesthetic ceramic materials for the dental CAD/CAM market. This segment of the dental market is experiencing rapid growth and strong tailwinds as more and more dental labs choose to adopt CAD/CAM technology.
pritidenta®’s main product offering consists of highly aesthetic zirconia (ZrO2) blank discs for use in crowns, bridges, full contour restorations, veneers, inlays and onlays. pritidenta®’s flagship product, the priti®multidisc, is made from high-purity zirconium dioxide and comes in three grades of translucency: opaque, translucent, highly translucent. It is available as a monochromatic disc in 16 classic shades or as a multicolour disc in seven different harmonious colour gradients.
The financing from Norgine Ventures will help the company to accelerate further product development and global commercial expansion.
Peter Stein, Managing Director at Norgine Ventures, said: “With our investment in pritidenta®, we are supporting an innovative healthcare technology company, which provides best-in-class ceramic materials to dental labs and milling centres. Led by an experienced management team and supported by TVM Capital Life Science, a top-tier venture capital investor, pritidenta® has demonstrated strong commercial momentum and is well placed to execute on its global expansion plan to capitalise on the rapidly growing digital market for dental prosthetics.”
Berthold Reusch, CEO of pritidenta, said: “We are pleased to welcome Norgine Ventures as a top-tier investment partner. This investment recognises the hard work put in by the pritidenta team to develop a dental CAD/CAM material portfolio of the highest quality at an attractive price point. Our flagship product, priti®multidisc, is the first zirconia product to achieve natural tooth appearance to rival lithium disilicate and glass ceramic, but with the strength of high-performance dental ceramics. With this investment from Norgine Ventures, we look forward to bringing our technology to new heights and into new markets.”
Stefan Fischer, General Partner at TVM Capital Life Science and Chairman of the Board of pritidenta GmbH, added: “Our investment rationale is validated by the commitment of Norgine Ventures. We are very confident that the current management team around Berthold Reusch is very well prepared to take the company’s international growth to the next level.”
Notes to Editors:
For further information please contact
Julien Michaux, Norgine Ventures, email@example.com
Alex Miller, Norgine Ventures, firstname.lastname@example.org
Berthold Reusch, pritidenta, email@example.com
Anke Riemer, pritidenta, firstname.lastname@example.org
Norgine Media Contact
Isabelle Jouin, Norgine, T: +441895453643
About Norgine and Norgine Ventures
Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2016, Norgine’s total revenue was EUR 368 million. Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply.
Norgine specialises in gastroenterology, hepatology, cancer and supportive care.
Norgine is headquartered in the Netherlands. Norgine owns a R&D site in Hengoed, Wales and two manufacturing sites in Hengoed, Wales and Dreux, France.
For further information, please visit www.norgine.com.
In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US.
For further information, please visit www.norgineventures.com.
NORGINE and the sail logo are trademarks of the Norgine group of companies.
pritidenta® GmbH is a young German high-tech firm and innovation leader in digital dental prosthetic materials. The main offering ranges from the best-in-class zirconia multidisc to next-generation ceramics, chair-side and 3D printing ceramic materials (under development) for crowns, bridges, full contour restorations, veneers, inlays and onlays. pritidenta focuses on the rapidly growing CAD/CAM and 3D printing segments of the dental market.
For further information, please visit www.pritidenta.com
About TVM Capital Life Science
TVM Capital Life Science is a group of independent investment advisories and fund managers for Venture Capital funds investing in innovative biotech, pharmaceutical, and medtech companies, with teams based in Munich and Montreal. Since 1984, TVM Capital Life Science has invested in more than 130 life science companies in Europe, Canada and the United States, currently managing in excess of €900 million from more than 50 investors.
For further information, please visit www.tvm-lifescience.com